Navigation Links
OncoGenex Pharmaceuticals Files Shelf Registration Statement
Date:6/26/2009

cancers, is designed to inhibit the production of a specific protein associated with treatment resistance; OGX-427 is in Phase 1 clinical development; SN2310 has completed the Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development.

OGX-011, OGX-427 and OGX-225 utilize second-generation antisense technology, licensed from Isis Pharmaceuticals (NASDAQ: ISIS), to effectively target and inhibit production of specific proteins in tumor cells. OncoGenex and Isis partnered in the successful discovery of OGX-011, OGX-427 and OGX-225 and with respect to OGX-011, in its initial development. In 2008, OncoGenex and Isis amended their OGX-011 agreement to provide OncoGenex with sole rights to OGX-011 and sole responsibility for development and related costs and partnering decisions, subject to financial obligations to Isis. OncoGenex is also solely responsible for development and related costs and partnering decisions regarding OGX-427 and OGX-225. Key intellectual property related to OGX-011, OGX-427 and OGX-225 were discovered by the University of British Columbia and the Vancouver Prostate Centre, and were exclusively licensed to OncoGenex.

More information about OncoGenex is available at www.oncogenex.com.

This press release contains forward-looking statements and 'forward-looking information' within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws, including statements concerning the shelf registration statement, the timing of any offerings under the shelf registration statement, the use of proceeds of any potential offerings of securities under the shelf registration statement, potential partnering of OGX-011, anticipated clinical development activities and t
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer
2. OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer
3. OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
4. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
5. OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
6. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
7. OncoGenex Reports First Quarter Financial Results
8. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
9. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
10. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
11. OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Doylestown, PA (PRWEB) January 14, 2014 Date: ... p.m. , Location: Warrington Country Club, 1360 Almshouse Road, Warrington, ... only national nonprofit organization solely dedicated to finding a cure ... those affected worldwide, will host its annual Crystal Ball on ...
(Date:1/14/2014)... Calif. , Jan. 14, 2014 As pet owners drew ... doubt many of them wrote: "Take better care of my furry ... even designer clothes and top-brand carrying cases to take the little ... parents might also feel compelled to buy some pricey toys at ...
(Date:1/14/2014)... iLab Solutions, the leader in core facility management ... Product Strategy. In this role, Michelle will work with current ... in the development of iLab products. Her main goal will ... to the scientific community by offering the most advanced, user-friendly, ...
(Date:1/14/2014)... 14, 2014   Kinaxis ®, provider of RapidResponse ®, ... and operations planning ( S&OP ) service, is proud to ... which will be held at the Hilton San Diego Bayfront, ... customer Elisabeth Kaszas , Director of Supply Chain at ...
Breaking Biology Technology:Hepatitis B Foundation to Host Annual Crystal Ball Gala 2New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2
... Md. , July 6 Novavax, Inc. (Nasdaq: ... Glenn , M.D., as the company,s Chief Scientific Officer who ... Chief Executive Officer of Novavax.  Previously, Dr. Glenn was Chief ... associate in international health at Johns Hopkins University,s School ...
... ,, BEIJING , ... Inc.,(Nasdaq: YONG ), ("Yongye" or the "Company") ... plant and animal nutrient products in, China , ... the annual,production capacity of its existing plant nutrient ...
... its discovery, graphenean unusual and versatile substance composed of ... excitement in the scientific community. Now, Nongjian(NJ) Tao, a ... has hit on a new way of making graphene, ... high-speed electronic devices. Along with collaborators from ...
Cached Biology Technology:Novavax Announces Appointment of Dr. Gregory Glenn as Chief Scientific Officer 2Novavax Announces Appointment of Dr. Gregory Glenn as Chief Scientific Officer 3Novavax Announces Appointment of Dr. Gregory Glenn as Chief Scientific Officer 4Yongye International Expands Its Existing Production Capacity by 50% and Provides Updates on Customer List Acquisition 2Yongye International Expands Its Existing Production Capacity by 50% and Provides Updates on Customer List Acquisition 3Yongye International Expands Its Existing Production Capacity by 50% and Provides Updates on Customer List Acquisition 4Graphene 2.0: A new approach to making a unique material 2Graphene 2.0: A new approach to making a unique material 3
(Date:4/17/2014)... Double-stapled peptide inhibits RSV infection , Respiratory ... lower respiratory tract infections, generating life-threating illness in ... preventive therapies are limited. RSV enters host cells ... a six-helix fusogenic bundle. Small interfering peptides that ... however, these peptides are highly susceptible to degradation. ...
(Date:4/17/2014)... that fish consumption advisories for expecting mothers are ... like persistent organic pollutants (POPs). , The ... University of Toronto Scarborough PhD student Matt Binnington ... levels of environmental contamination, a mother,s compliance with ... body influenced exposure in her children. , Their ...
(Date:4/17/2014)... Our eyes not ... with a continuous stream of information about our own movements. ... a car the world glides by us and leaves ... our brain calculates self-motion from this "optic flow". This way, ... during our own movements. Together with biologists from the University ...
Breaking Biology News(10 mins):JCI online ahead of print table of contents for April 17, 2014 2JCI online ahead of print table of contents for April 17, 2014 3JCI online ahead of print table of contents for April 17, 2014 4JCI online ahead of print table of contents for April 17, 2014 5JCI online ahead of print table of contents for April 17, 2014 6Fish consumption advisories fail to cover all types of contaminants 2How vision makes sure that little fish do not get carried away 2How vision makes sure that little fish do not get carried away 3How vision makes sure that little fish do not get carried away 4
... ANN ARBOR, MI -- During pregnancy, many women ... uveitis. Now, scientists have described a biological mechanism responsible ... explain the remission. The expression of an enzyme ... in pregnant women compared to non-pregnant women, according to ...
... have discovered the oldest mammalian tooth marks yet on ... They report their findings in a paper published online ... Nicholas Longrich of Yale University and Michael J. ... across several of the bones while studying the collections ...
... (June 16, 2010) A research team from McGill ... in mouse models when implanted monocytes - a type ... immune system - helped preserve cardiac function following a ... in the current issue of Cell Transplantation ...
Cached Biology News:Why do certain diseases go into remission during pregnancy? 2Dinosaur-chewing mammals leave behind oldest known tooth marks 2Specific blood-derived cells promote survival in heart attack model 2
...
... BacVector Insect Cell Medium is optimized ... Ea4 Insect Cells. In this protein-free medium, ... 1 * 107 cells/ml with viabilities above ... plaque assays, where color from X-gluc staining ...
...
...
Biology Products: